TICKERNOMICS Sign up
Last Update: 2023-12-23 06:04:29
BioRestorative Therapies Inc. ( BRTX ) https://www.biorestorative.com
1.74USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-41.81%
BRTX
SPY
30.72%
-94.82%
BRTX
SPY
112.82%
-99.93%
BRTX
SPY
201.04%
-100.00%
BRTX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
7.95
-1.65
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.64
61.08
0.62
-33.93
0.00
0.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-10112.19
100.00
-12800.81
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
212.93
-115.29
-79.32
50.50
Other Earnings and Cash Flow Stats:
BioRestorative Therapies Inc. ( BRTX ) Net Income TTM ($MM) is -14.22
BioRestorative Therapies Inc. ( BRTX ) Operating Income TTM ($MM) is -18.18
BioRestorative Therapies Inc. ( BRTX ) Owners' Earnings Annual ($MM) is 0.00
BioRestorative Therapies Inc. ( BRTX ) Current Price to Owners' Earnings ratio is 0.00
BioRestorative Therapies Inc. ( BRTX ) EBITDA TTM ($MM) is -18.19
BioRestorative Therapies Inc. ( BRTX ) EBITDA Margin is -12800.81%
Capital Allocation:
BioRestorative Therapies Inc. ( BRTX ) has paid 0.00 dividends per share and bought back -0.928628 million shares in the past 12 months
BioRestorative Therapies Inc. ( BRTX ) has reduced its debt by 0.134031 million USD in the last 12 months
Capital Structure:
BioRestorative Therapies Inc. ( BRTX ) Interest-bearing Debt ($MM) as of last quarter is 0
BioRestorative Therapies Inc. ( BRTX ) Annual Working Capital Investments ($MM) are -1
BioRestorative Therapies Inc. ( BRTX ) Book Value ($MM) as of last quarter is 12
BioRestorative Therapies Inc. ( BRTX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
BioRestorative Therapies Inc. ( BRTX ) has 2 million in cash on hand as of last quarter
BioRestorative Therapies Inc. ( BRTX ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
BioRestorative Therapies Inc. ( BRTX ) has 4 common shares outstanding as of last quarter
BioRestorative Therapies Inc. ( BRTX ) has 0 million USD of preferred stock value
Academic Scores:
BioRestorative Therapies Inc. ( BRTX ) Altman Z-Score is -14.73 as of last quarter
BioRestorative Therapies Inc. ( BRTX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BioRestorative Therapies Inc. ( BRTX ) largest shareholder is owning shares at 0.00 ($MM) value
Dale Broadrick(an insider) Sold 250 shares of BioRestorative Therapies Inc. ( BRTX ) for the amount of $470.00 on 2023-12-01
18.93% of BioRestorative Therapies Inc. ( BRTX ) is held by insiders, and 16.82% is held by institutions
BioRestorative Therapies Inc. ( BRTX ) went public on 2007-07-27
Other BioRestorative Therapies Inc. ( BRTX ) financial metrics:
FCF:-5.82
Unlevered Free Cash Flow:0.00
EPS:-0.07
Operating Margin:-10112.19
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2.60
Beta:50.50
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BioRestorative Therapies Inc. ( BRTX ) :
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.